Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

Eugenio Baraldi, Marcello Lanari, Paolo Manzoni, Giovanni A Rossi, Silvia Vandini, Alessandro Rimini, Costantino Romagnoli, Pierluigi Colonna, Andrea Biondi, Paolo Biban, Giampietro Chiamenti, Roberto Bernardini, Marina Picca, Marco Cappa, Giuseppe Magazzù, Carlo Catassi, Antonio Francesco Urbino, Luigi Memo, Gianpaolo Donzelli, Carlo Minetti, Francesco Paravati, Giuseppe Di Mauro, Filippo Festini, Susanna Esposito, Giovanni Corsello, Eugenio Baraldi, Marcello Lanari, Paolo Manzoni, Giovanni A Rossi, Silvia Vandini, Alessandro Rimini, Costantino Romagnoli, Pierluigi Colonna, Andrea Biondi, Paolo Biban, Giampietro Chiamenti, Roberto Bernardini, Marina Picca, Marco Cappa, Giuseppe Magazzù, Carlo Catassi, Antonio Francesco Urbino, Luigi Memo, Gianpaolo Donzelli, Carlo Minetti, Francesco Paravati, Giuseppe Di Mauro, Filippo Festini, Susanna Esposito, Giovanni Corsello

Abstract

Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to identify viruses involved, may have a role in reducing hospital transmission of the infection. Criteria for hospitalization include low oxygen saturation (<90-92%), moderate-to-severe respiratory distress, dehydration and presence of apnea. Children with pre-existing risk factors should be carefully assessed.To date, there is no specific treatment for viral bronchiolitis, and the mainstay of therapy is supportive care. This consists of nasal suctioning and nebulized 3% hypertonic saline, assisted feeding and hydration, humidified O2 delivery. The possible role of any pharmacological approach is still debated, and till now there is no evidence to support the use of bronchodilators, corticosteroids, chest physiotherapy, antibiotics or antivirals. Nebulized adrenaline may be sometimes useful in the emergency room. Nebulized adrenaline can be useful in the hospital setting for treatment as needed. Lacking a specific etiological treatment, prophylaxis and prevention, especially in children at high risk of severe infection, have a fundamental role. Environmental preventive measures minimize viral transmission in hospital, in the outpatient setting and at home. Pharmacological prophylaxis with palivizumab for RSV bronchiolitis is indicated in specific categories of children at risk during the epidemic period. Viral bronchiolitis, especially in the case of severe form, may correlate with an increased incidence of recurrent wheezing in pre-schooled children and with asthma at school age.The aim of this document is to provide a multidisciplinary update on the current recommendations for the management and prevention of bronchiolitis, in order to share useful indications, identify gaps in knowledge and drive future research.

References

    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598. doi: 10.1056/NEJMoa0804877.
    1. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774–1793. doi: 10.1542/peds.2006-2223.
    1. Zorc JJ, Hall CB. Bronchiolitis: Recent evidence on diagnosis and management. Pediatrics. 2010;125(2):342–349. doi: 10.1542/peds.2009-2092.
    1. Bosis S, Esposito S, Niesters HG, Zuccotti GV, Marseglia G, Lanari M, Zuin G, Pelucchi C, Osterhaus AD, Principi N. Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences. Clin Microbiol Infect. 2008;14(7):677–684. doi: 10.1111/j.1469-0691.2008.02016.x.
    1. Paranhos-Baccala G, Komurian-Pradel F, Richard N, Vernet G, Lina B, Floret D. Mixed respiratory virus infections. J Clin Virol. 2008;43(4):407–410. doi: 10.1016/j.jcv.2008.08.010.
    1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–186. doi: 10.1001/jama.289.2.179.
    1. Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev. 2012;88(Suppl 2):S34–S41. doi: 10.1016/S0378-3782(12)70012-9.
    1. Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GA, Merolla R, Zuccotti GV, Salvioli GP, Investigators RADAR. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 2002;33(6):458–465. doi: 10.1002/ppul.10047.
    1. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–1052. doi: 10.1136/thx.2009.121582.
    1. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–545. doi: 10.1016/S0140-6736(98)10321-5.
    1. Lenney W, Boner AL, Bont L, Bush A, Carlsen KH, Eber E, Fauroux B, Götz M, Greenough A, Grigg J, Hull J, Kimpen J, Sánchez Luna M, De Benedictis FM. Medicines used in respiratory diseases only seen in children. Eur Respir J. 2009;34(3):531–551. doi: 10.1183/09031936.00166508.
    1. Da Dalt L, Bressan S, Martinolli F, Perilongo G, Baraldi E. Treatment of bronchiolitis: state of the art. Early Hum Dev. 2013;89(Suppl 1):S31–S36. doi: 10.1016/S0378-3782(13)70011-2.
    1. Bronchiolitis Guideline Team, Cincinnati Children’s Hospital Medical Center . Evidence Based Clinical Practice Guideline for Medical Management of Bronchiolitis in Infants 1 Year of Age or Less Presenting with a First Time Episode. Cincinnati: Cincinnati Children’s Hospital Medical Center; 2010.
    1. Management of Bronchiolitis in Infants . The Hospital for Sick Children, Clinical Practice Guideline. 2011. Last Modified.
    1. Waris M, Meurman O, Mufson MA, Ruuskanen O, Halonen P. Shedding of infectious virus and virus antigen during acute infection with respiratory syncytial virus. J Med Virol. 1992;38(2):111–116. doi: 10.1002/jmv.1890380208.
    1. Principi N, Esposito S. Antigen-based assays for the identification of influenza virus and respiratory syncytial virus: why and how to use them in pediatric practice. Clin Lab Med. 2009;29(4):649–660. doi: 10.1016/j.cll.2009.07.006.
    1. Meerhoff TJ, Houben ML, Coenjaerts FE, Kimpen JL, Hofland RW, Schellevis F, Bont LJ. Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab versus nasopharyngeal aspirate using real-time polymerase chain reaction. Eur J Clin Microbiol Infect Dis. 2010;29(4):365–371. doi: 10.1007/s10096-009-0865-7.
    1. Princess Margaret Hospital for Children, Melbourne. 2010.
    1. Scottish Intercollegiate Guidelines Network (SIGN) Bronchiolitis in Children. 2006. Guideline no. 91.
    1. Milési C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, Cambonie G. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Med. 2013;39(6):1088–1094. doi: 10.1007/s00134-013-2879-y.
    1. Arora B, Mahajan P, Zidan MA, Sethuraman U. Nasopharyngeal airway pressures in bronchiolitis patients treated with high-flow nasal cannula oxygen therapy. Pediatr Emerg Care. 2012;28(11):1179–1184. doi: 10.1097/PEC.0b013e318271a671.
    1. Hilliard TN, Archer N, Laura H, Heraghty J, Cottis H, Mills K, Ball S, Davis P. Pilot study of vapotherm oxygen delivery in moderately severe bronchiolitis. Arch Dis Child. 2012;97(2):182–183. doi: 10.1136/archdischild-2011-301151.
    1. Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E. High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. Eur J Pediatr. 2013;172:1649–1656. doi: 10.1007/s00431-013-2094-4.
    1. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;7:CD006458.
    1. Morawetz D, Cheah E, Barton R, Standish J, Connell TG. Is nebulised hypertonic saline useful as an adjunctive treatment for acute bronchiolitis in infants and children less than 24 months of age? J Paediatr Child Health. 2011;47(12):922–926. doi: 10.1111/j.1440-1754.2011.02388.x.
    1. Ralston S. Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h. Evid Based Med. 2011;16(3):82–83. doi: 10.1136/ebm1188.
    1. Kuzik BA, Al-Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S, Gander S. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 2007;151(3):266–270. doi: 10.1016/j.jpeds.2007.04.010.
    1. Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol. 2010;45(1):36–40. doi: 10.1002/ppul.21185.
    1. Ralston S, Hill V, Martinez M. Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis. Pediatrics. 2010;126(3):e520–e525. doi: 10.1542/peds.2009-3105.
    1. Turner T, Wilkinson F, Harris C, Mazza D, Health for Kids Guideline Development Group Evidence based guideline for the management of bronchiolitis. Aust Fam Physician. 2008;37(6):6–13.
    1. Mussman GM, Parker MW, Statile A, Sucharew H, Brady PW. Suctioning and length of stay in infants hospitalized with bronchiolitis. JAMA Pediatr. 2013;167(5):414–421. doi: 10.1001/jamapediatrics.2013.36.
    1. Babl FE, Sheriff N, Neutze J, Borland M, Oakley E. Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study. Pediatr Emerg Care. 2008;24(10):656–658. doi: 10.1097/PEC.0b013e318188498c.
    1. Oakley E, Babl FE, Acworth J, Borland M, Kreiser D, Neutze J, Theophilos T, Donath S, South M, Davidson A, Paediatric Research in Emergency Departments International Collaborative A prospective randomised trial comparing nasogastric with intravenous hydration in children with bronchiolitis (protocol): the comparative rehydration in bronchiolitis study (CRIB) BMC Pediatr. 2010;1:10–37.
    1. Luu R, Dewitt PE, Reiter PD, Dobyns EL, Kaufman J. Hyponatremia in Children with Bronchiolitis Admitted to the Pediatric Intensive Care Unit Is Associated with Worse Outcomes. J Pediatr. 2013;163:1652–1656. doi: 10.1016/j.jpeds.2013.06.041.
    1. Umoren R, Odey F, Meremikwu MM. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. Cochrane Database Syst Rev. 2011;1:CD006435.
    1. Roque I, Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2012;15:2.
    1. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2010;12:CD001266.
    1. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, Klassen TP, Patel H, Fernandes RM. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011;6:CD003123.
    1. Skjerven HO, Hunderi JO, Brügmann-Pieper SK, Brun AC, Engen H, Eskedal L, Haavaldsen M, Kvenshagen B, Lunde J, Rolfsjord LB, Siva C, Vikin T, Mowinckel P, Carlsen KH, Lødrup Carlsen KC. Racemic adrenaline and inhalation strategies in acute bronchiolitis. N Engl J Med. 2013;368(24):2286–2293. doi: 10.1056/NEJMoa1301839.
    1. Blom D, Ermers M, Bont L, Van Aalderen WM, Van Woensel JB. Inhaled corticosteroids during acute bronchiolitis in the prevention of post bronchiolitic wheezing. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004881. Review. Update in. Cochrane Database Syst Rev. 2011;1:CD004881.
    1. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, Johnson DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013;6:CD004878.
    1. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, Ruddy RM, Malik B, Nelson KA, Bregstein JS, Brown KM, Denenberg MN, Lillis KA, Cimpello LB, Tsung JW, Borgialli DA, Baskin MN, Teshome G, Goldstein MA, Monroe D, Dean JM, Kuppermann N. Bronchiolitis study group of the pediatric emergency care applied research network (pecarn). a multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357(4):331–339. doi: 10.1056/NEJMoa071255.
    1. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, Mitton C, Gouin S, Bhatt M, Joubert G, Black KJ, Turner T, Whitehouse S, Klassen TP. Pediatric emergency research canada (PERC) epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009;360(20):2079–2089. doi: 10.1056/NEJMoa0900544.
    1. Spurling GK, Doust J, Del Mar CB, Eriksson L. Antibiotics for bronchiolitis in children. Cochrane Database Syst Rev. 2011;6:CD005189.
    1. Pinto LA, Pitrez PM, Luisi F, De Mello PP, Gerhardt M, Ferlini R, Barbosa DC, Daros I, Jones MH, Stein RT, Marostica PJ. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes:a randomized, double-blinded, and placebo-controlled clinical trial. J Pediatr. 2012;161(6):1104–1108. doi: 10.1016/j.jpeds.2012.05.053.
    1. Ventre K, Randolph A, WITHDRAWN Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2010;5:CD000181.
    1. Zedan M, Gamil N, El-Assmy M, Fayez E, Nasef N, Fouda A, Settin A. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. Allergy Asthma Proc. 2010;31(2):147–153. doi: 10.2500/aap.2010.31.3324.
    1. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, Zuker M, Tal G, Mandelberg A. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics. 2008;122(6):e1249–e1255. doi: 10.1542/peds.2008-1744.
    1. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–860. doi: 10.1164/rccm.200706-910OC.
    1. Bisgaard H. Study group on montelukast and respiratory syncytial virus. a randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167(3):379–383. doi: 10.1164/rccm.200207-747OC.
    1. Proesmans M, Sauer K, Govaere E, Raes M, De Bilderling G, De Boeck K. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr. 2009;98(11):1830–1834. doi: 10.1111/j.1651-2227.2009.01463.x.
    1. Kim CK, Choi J, Kim HB, Callaway Z, Shin BM, Kim JT, Fujisawa T, Koh YY. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr. 2010;156(5):749–754. doi: 10.1016/j.jpeds.2009.12.001.
    1. Enriquez A, Chu IW, Mellis C, Lin WY. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. 2012;11:CD008395.
    1. Ramesh P, Samuels M. Are methylxanthines effective in preventing or reducing apnoeic spells in infants with bronchiolitis? Arch Dis Child. 2005;90(3):321–322. doi: 10.1136/adc.2004.068825.
    1. Sajit NT, Steggall M, Padmakumar B. Apnoeas in bronchiolitis: is there a role for caffeine? Arch Dis Child. 2005;90(4):438. doi: 10.1136/adc.2004.064824.
    1. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009;155(5):728–733. doi: 10.1016/j.jpeds.2009.04.063.
    1. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis. 2000;31(2):590–596. doi: 10.1086/313960.
    1. Sattar SA, Springthorpe VS, Tetro J, Vashon R, Keswick B. Hygienic hand antiseptics: should they not have activity and label claims against viruses? Am J Infect Control. 2002;30(6):355–372. doi: 10.1067/mic.2002.124532.
    1. Isaacs D, Dickson H, O'Callaghan C, Sheaves R, Winter A, Moxon ER. Handwashing and cohorting in prevention of hospital acquired infections with respiratory syncytial virus. Arch Dis Child. 1991;66(2):227–231. doi: 10.1136/adc.66.2.227.
    1. Centers for Disease Control and Prevention (CDC) Respiratory Syncytial Virus, Transmission and Prevention. 2010.
    1. Groothuis J, Bauman J, Malinoski F, Eggleston M. Strategies for prevention of RSV nosocomial infection. J Perinato. 2008;28(5):319–323. doi: 10.1038/jp.2008.37.
    1. Bont L. Nosocomial RSV, infection control and outbreak management. Paediatr Respir Rev. 2009;10(Suppl 1):16–17. doi: 10.1016/S1526-0542(09)70008-9.
    1. Karanfil LV, Conlon M, Lykens K, Masters CF, Forman M, Griffith ME, Townsend TR, Perl TM. Reducing the rate of nosocomially transmitted respiratory syncytial virus. Am J Infect Control. 1999;27(2):91–96. doi: 10.1016/S0196-6553(99)70087-8.
    1. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics. 2000;106(3):520–526. doi: 10.1542/peds.106.3.520.
    1. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Jr, Carlin D, Connor E. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110–115. doi: 10.1097/00006454-199802000-00006.
    1. Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH, Jr, Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(9):787–791. doi: 10.1097/00006454-199809000-00007.
    1. American Academy of Pediatrics Policy statement – modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–1701. doi: 10.1542/peds.2009-2345.
    1. Null D, Jr, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH, Jr, Connor E. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J. 2005;24(11):1021–1023. doi: 10.1097/.
    1. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, Connor EM, Sondheimer HM, Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–540. doi: 10.1067/S0022-3476(03)00454-2.
    1. Figueras Aloy J, Quero J, Doménech E, López Herrera MC, Izquierdo I, Losada A, Perapch J, Sánchez-Luna M. Comité de estándares de la sociedad española de neonatología. [recommendations for the prevention of respiratory syncytial virus infection] An Pediatr (Barc) 2005;63(4):357–362. doi: 10.1157/13079818.
    1. Robinson J. Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16(8):487–490.
    1. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS)Acta Neonatologica Pediatrica 2004, 18:19–30.
    1. Lanari M, Prinelli F, Adorni F, Di Santo S, Faldella G, Silvestri M, Musico M. Collaborators, on behalf of the ‘italian neonatology study group on rsv infections’. maternal milk protects infants against bronchiolitis during the first year of life. results from an italian cohort of newborns. Early Hum Dev. 2013;89(1):S51–S57. doi: 10.1016/S0378-3782(13)70016-1.
    1. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, Rovers M, Bont L. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6):e1513–e1520. doi: 10.1542/peds.2010-3054.
    1. Camargo CA, Jr, Rifas-Shiman SL, Litonjua AA, Rich-Edwards JW, Weiss ST, Gold DR, Kleinman K, Gillman MW. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr. 2007;85(3):788–795.
    1. Midulla F, Pierangeli A, Cangiano G, Bonci E, Salvadei S, Scagnolari C, Moretti C, Antonelli G, Ferro V, Papoff P. Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up. Eur Respir J. 2012;39(2):396–402. doi: 10.1183/09031936.00188210.
    1. Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M. Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy. Pediatr Pulmonol. 2014;49:318–325. doi: 10.1002/ppul.22842.
    1. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L, Dutch RSV. Neonatal Network Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799. doi: 10.1056/NEJMoa1211917.
    1. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Resp Rev. 2009;10:148–153. doi: 10.1016/j.prrv.2009.06.003.
    1. Afghani B, Ngo T. Severe respiratory syncytial virus infection in term infants with genetic or other underlying disorders. Pediatrics. 2008;121:868–869. doi: 10.1542/peds.2008-0035.
    1. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Tsutsumi H, Yokota S, Itoh S, Surveillance Committee for Severe RSV Infection Surveillance committee for severe rsv infection. nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in japan. J Infect Chemother. 2011;17:254–263. doi: 10.1007/s10156-010-0121-1.
    1. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, Hornschuh F, Groothuis JR, Simon A, DSM RSV Ped Study Group Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26:485–491. doi: 10.1097/INF.0b013e31805d01e3.
    1. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43:169–174. doi: 10.1002/ppul.20751.
    1. Winterstein AG, Eworuke E, Dandan X, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol. 2013;48:874–884. doi: 10.1002/ppul.22711.
    1. Bloemers BL, Van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis – a prospective birth-cohort study. Pediatrics. 2007;120:e1076–e1081. doi: 10.1542/peds.2007-0788.
    1. Zachariah P, Ruttenber M, Simoes EA. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr. 2012;160:827–831. doi: 10.1016/j.jpeds.2011.11.004.
    1. Van Beek D, Paes B, Bont L. Clin Dev Immunol. 2013. Increased risk of RSV infection in children with down's syndrome: clinical implementation of prophylaxis in the european union; p. 801581.
    1. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315:77–81. doi: 10.1056/NEJM198607103150201.
    1. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe RSV disease in children with cancer: the importance of lymphopenia and young age. Pediatrics. 2008;121:235–243. doi: 10.1542/peds.2007-1102.
    1. Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG. Children’s oncology group. respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the children’s oncology group. Pediatr Blood Cancer. 2008;51:784. doi: 10.1002/pbc.21710.
    1. Simon A, Muller A, Khurana K, Engelhart S, Exner M, Schildgen O, Eis-Hübinger AM, Kamin W, Schaible T, Wadas K, Ammann RA, Wilkesmann A, DSM RSV Paed Study Group Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection – results from a prospective multicenter German surveillance study. Int J Hyg Environ Health. 2008;211:241–250. doi: 10.1016/j.ijheh.2007.07.020.
    1. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99–103. doi: 10.1136/adc.2008.139188.
    1. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, Svendsen AL, Nielsen BW. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child. 2009;94:785–789. doi: 10.1136/adc.2008.143057.
    1. Lanari M, Rossi GA, Merolla R, Di Luzio Paparatti U. High risk of nosocomial-acquired RSV infection in children with congenital heart disease. J Pediatr. 2004;145(1):140. doi: 10.1016/j.jpeds.2004.03.029.
    1. Cabalka AK. “Physiologic risk factors for respiratory viral infections and immunoprophylaxis for RSV in young children with CHD”. Pediatr Infect Dis J. 2004;23:S41–S45. doi: 10.1097/01.inf.0000108220.94201.1a.
    1. Khongphatthanayothin A, Wong PC, Samara Y, Newth CJ, Wells WJ, Starnes VA, Chang AC. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med. 1999;27:1974–1981. doi: 10.1097/00003246-199909000-00042.
    1. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143(5 Suppl):S142–S149. doi: 10.1067/S0022-3476(03)00514-6.
    1. Bollettino della Società Italiana di Cardiologia Pediatrica Anno 13 . La Prevenzione Della Malattia Da Virus Respiratorio Sinciziale Nei Bambini Con Cardiopatia Congenita O Acquisita Nell’infanzia. 2006. Raccomandazioni della Società Italiana di Cardiologia Pediatrica (SICP)

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi